Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

AIM
AIM ImmunoTech Inc.
stock NYSEAMERICAN

At Close
Jan 8, 2026 3:59:30 PM EST
1.32USD+2.326%(+0.03)33,129
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jan 7, 2026 8:49:30 AM EST
1.26USD-2.326%(-0.03)0
After-hours
Jan 6, 2026 4:07:30 PM EST
1.30USD+1.273%(+0.02)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 26, 2022
08:05AM EST  AIM ImmunoTech management to participate in webinar Thursday, January 27th from 2:00 pm - 3:00 pm ET   GlobeNewswire Inc
Jan 24, 2022
08:00AM EST  Chemokine-modulating IP chemo-immunotherapy combination demonstrated to be well tolerated, and associated with interferon stimulated gene changes that favor cytotoxic T lymphocytes chemoattraction and function   GlobeNewswire Inc
Jan 19, 2022
08:35AM EST  AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks   GlobeNewswire Inc
Dec 16, 2021
11:27AM EST  From Benzinga's All-Access Conference: AIM ImmunoTech CEO, Thomas Equels Says Co Has Multiple Oncology Clinical Trials In The Process Currently   Benzinga
11:23AM EST  From Benzinga's All-Access Conference: AIM ImmunoTech CEO, Thomas Equels Begins Presenting   Benzinga
Dec 9, 2021
09:46PM EST  AIM ImmunoTech's Ampligen Safety Data Presented At Eighth European Scientific Working Group On Influenza   Benzinga
07:20AM EST  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that safety data on its drug Ampligen was recently presented at the Eighth European Scientific Working Group on Influenza (ESWI) virtual conference in Salzburg, Austria, on December 4-7, 2021. The conference also included research on COVID-19 and respiratory syncytial virus.   GlobeNewswire Inc
Dec 6, 2021
07:25AM EST  AIM ImmunoTech CEO To Participate In Two Upcoming Investor Conferences   Benzinga
07:25AM EST  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas Equels, Chief Executive Officer of AIM, will be participating in two upcoming investor conferences.   GlobeNewswire Inc
Nov 30, 2021
09:01AM EST  TRADE X Secures Additional Debt Financing from Forbright Bank and a Global   PR Newswire
Nov 16, 2021
07:00AM EST  AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the third quarter ended September 30, 2021 and provides a business update.   GlobeNewswire Inc
Nov 11, 2021
03:55AM EST  Earnings Scheduled For November 11, 2021   Benzinga
Oct 19, 2021
07:26AM EDT  AIM ImmunoTech Submits IND And Accompanying Fast Track Application For Phase 2 Trial Of Ampligen In Patients With Locally Advanced Or Metastatic Late-Stage Pancreatic Cancer   Benzinga
07:25AM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the U.S. Food and Drug Administration (FDA) for a planned Phase 2 study of the companys drug Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer.   GlobeNewswire Inc
Oct 6, 2021
07:26AM EDT  AIM ImmunoTech Highlights Publication Of Phase 1 Clinical Study On Ampligen As An Intranasal Therapy   Benzinga
07:25AM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) today released detailed safety data from a Phase 1 clinical study which supports the companys belief that its drug Ampligen has significant potential as an intranasal therapeutic for COVID-19.   GlobeNewswire Inc
Oct 4, 2021
09:23AM EDT  AIM ImmunoTech Says Has Finalized Protocol For Planned Phase 2 Study Of Ampligen   Benzinga
09:20AM EDT  AIM ImmunoTech Provides Clinical Updates on Planned Phase 2 Study   GlobeNewswire Inc
08:42AM EDT  IIROC Trade Resumption - AIM   PR Newswire
08:09AM EDT  IIROC Trading Halt - AIM   PR Newswire
Sep 30, 2021
09:27AM EDT  AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses   Benzinga
07:43AM EDT  The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug   Benzinga
06:09AM EDT  AIM ImmunoTech, HVIVO Sign Clinical Trial Agreement For Phase 2a Human Challenge Trial Of Ampligen   RTTNews
06:03AM EDT  AIM ImmunoTech Announces Clinical Trial Agreement For A Phase 2a Human Challenge Trial Of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses   Benzinga
06:00AM EDT  AIM ImmunoTech Inc. (NYSE American:AIM) today announced that AIM and hVIVO have a signed Clinical Trial Agreement (CTA) for a Phase 2a Human Challenge Trial (HCT) to test the companys drug Ampligen as a potential intranasal prophylactic using a human rhinovirus (HRV-16, a common cold virus) and influenza A virus (H3N2).   GlobeNewswire Inc
Sep 28, 2021
02:50PM EDT  AIM ImmunoTech Plans To Evaluate Two Forms Of Ampligen In Early-COVID-19 Disease   Benzinga
09:20AM EDT  AIM ImmunoTech Submits Pre-IND Application To FDA For Phase 2 Clinical Studies Of Ampligen As A Potential Early-Onset Therapeutic For COVID-19   Benzinga
09:20AM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and Drug Administration (FDA) for two separate Phase 2 clinical studies to study the potential of Ampligen as both an infusion and an intranasal therapy for early-onset COVID-19, the disease caused by SARS-CoV-2.   GlobeNewswire Inc
Sep 27, 2021
09:21AM EDT  AIM ImmunoTech Files Provisional Patent Application For Ampligen As Early-Onset Intranasal Therapy That May Also Confer Enhanced Immunity To A Wide Range Of Respiratory Viruses   Benzinga
09:20AM EDT  AIM ImmunoTech Files Provisional Patent Application for Ampligen   GlobeNewswire Inc
Sep 21, 2021
07:26AM EDT  AIM ImmunoTech Says FDA Meeting Request Has Been Deemed Sufficient For Transfer To FDA's Division Of Neurology   Benzinga
07:25AM EDT  AIM ImmunoTech Announces Positive Progress on Requested FDA   GlobeNewswire Inc
Sep 20, 2021
09:19AM EDT  AIM ImmunoTech Says A Meeting Is Scheduled For Sept. 24 To Review Phase 2a Human Challenge Trial Using Ampligen   Benzinga
09:15AM EDT  AIM ImmunoTech Provides an Update on Its Pending Phase 2a Human   GlobeNewswire Inc
Sep 16, 2021
09:01AM EDT  TRADE X Announces Data Integration Agreement with Leading Automotive Data   PR Newswire
Sep 8, 2021
12:22PM EDT  AIM ImmunoTech To Test Ampligen In Post-COVID-19 Cognitive Dysfunction   Benzinga
09:06AM EDT  AIM ImmunoTech Submits Pre-IND Application To FDA For Phase 2 Clinical Study Of Ampligen As Potential Infusion Therapy For Post-COVID-19 Cognitive Dysfunction   Benzinga
09:00AM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of Ampligen as a potential infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD).   GlobeNewswire Inc
Sep 7, 2021
09:12AM EDT  TRADE X Announces Acquisition of Automotive Export Company Techlantic Ltd.   PR Newswire
Aug 30, 2021
09:01AM EDT  TRADE X Announces US$10 Million in Equity Funding to Continue Global Expansion   PR Newswire
Aug 25, 2021
09:03AM EDT  AIM ImmunoTech Reports Filed Provisional Patent Application For Use Of Ampligen As Both Intranasal, IV Therapy For Post-COVID-19 Cognitive Dystfunction   Benzinga
09:00AM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) today provided an update on the companys efforts to develop its drug Ampligen as a potential intranasal therapeutic for COVID-19, including the announcement of a new provisional patent application for Ampligen as both an intranasal and an intravenous therapy for what AIM describes as Post-COVID-19 Cognitive Dysfunction (PCCD).   GlobeNewswire Inc
Aug 17, 2021
09:13AM EDT  AIM ImmunoTech Q2 EPS $(0.12) Misses $(0.08) Estimate, Sales $23.00K Miss $350.00K Estimate   Benzinga
09:00AM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update.   GlobeNewswire Inc
Aug 16, 2021
07:52AM EDT  AIM ImmunoTech Names CEO Thomas Equels To Board Of Directors Of BioFlorida Inc   RTTNews
07:25AM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that CEO Thomas K. Equels has been appointed to the Board of Directors of BioFlorida Inc., the states life sciences industry association.   GlobeNewswire Inc
Aug 13, 2021
04:12AM EDT  Earnings Scheduled For August 13, 2021   Benzinga
Jul 9, 2021
08:26AM EDT  AIM ImmunoTech Inc. (AIM) said that it has signed a contract to sponsor a Phase 2a Human Challenge Trial to test the company's drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV--common cold virus-- and Influenza.   RTTNews
08:07AM EDT  AIM ImmunoTech Announces Phase 2a HCT To Test Ampligen As Intranasal Antiviral Prophylactic Therapy   RTTNews
07:27AM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the companys drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza.   GlobeNewswire Inc
07:26AM EDT  AIM ImmunoTech Reports Phase 2a Human Challenge Trial To Test Its Drug Ampligen As Intranasal Antiviral Prophylactic Therapy   Benzinga
Jul 6, 2021
02:15PM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 2021, to discuss recent accomplishments and upcoming milestones. Investors and other interested parties are invited to submit questions to management prior to the call's start via email to aim@crescendo-ir.com.   GlobeNewswire Inc
Jun 21, 2021
09:02AM EDT  AIM ImmunoTech Says Completes All Treatments In Phase 1 Human Safety Study Of Intranasal Administration Of Ampligen   Benzinga
09:00AM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that all subjects have completed treatment in the Companys Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as a potential intranasal therapy. A final study report is expect in the third quarter of 2021.   GlobeNewswire Inc
Jun 14, 2021
07:18AM EDT  AIM ImmunoTech Highlights Ampligen Featured in Peer-Reviewed Journal Cancers As A Potential Therapy For Cancer Patients With SARS-CoV-2   Benzinga
07:15AM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its drug Ampligen has been featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal Cancers as a potential treatment option for cancer patients who are infected with SARS-CoV-2.   GlobeNewswire Inc
May 27, 2021
08:45AM EDT  AIM ImmunoTech Reports 2-Year Extension Of Deal With Shenzhen Smoore Technology To Develop, Test New Inhalation Delivery Device For Ampligen, No Terms Disclosed   Benzinga
08:45AM EDT  AIM ImmunoTech Announces Two Year Extension of Agreement with   GlobeNewswire Inc
May 26, 2021
09:16AM EDT  AIM ImmunoTech Reports Completed Dosing Of Cohort 3 In Phase 1 Study To Assess Safety, Tolerability, Biological Activity Of Ampligen As An Intranasal Therapy   Benzinga
09:15AM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 3 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse events.   GlobeNewswire Inc
May 18, 2021
07:34AM EDT  AIM ImmunoTech Q1 EPS $(0.08) Up From $(0.22) YoY   Benzinga
07:30AM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the first quarter ended March 31, 2021.   GlobeNewswire Inc
May 14, 2021
04:03AM EDT  Earnings Scheduled For May 14, 2021   Benzinga
May 6, 2021
01:48PM EDT  AIM ImmunoTech 8-K Shows Co. Filed 1 US Provisional Patent Application For Co.'s Ampligen As Potential Therapeutic To Possibly Slow, Halt, Reverse Progression Of Alzheimer's   Benzinga
May 3, 2021
07:30AM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) announces that Thomas K. Equels, CEO of AIM ImmunoTech, participated in a Fireside Chat video interview with Ed Woo, Director of Research & Senior Analyst at Ascendiant Capital Markets.   GlobeNewswire Inc
Apr 27, 2021
07:20AM EDT  AIM ImmunoTech Completes Dosing Of Cohort 2 In Phase 1 Study Of Ampligen, Reporting No Serious Adverse Events   Benzinga
07:15AM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 2 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting no serious adverse events (SAE). AIM also reported no SAEs in Cohort 1. The study will proceed with enrollment into Cohort 3.   GlobeNewswire Inc
Apr 7, 2021
10:46AM EDT  AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study   Benzinga
09:17AM EDT  AIM ImmunoTech Announces Safety Data In First Cohort Of Phase 1 Clinical Study Investigating Intranasal Administration Of Ampligen As Potential Prophylaxis Or Treatment For COVID-19 And Other Respiratory Viral Diseases   Benzinga
09:15AM EDT  AIM ImmunoTech Announces Positive Safety Data in First Cohort of   GlobeNewswire Inc
07:55AM EDT  AIM ImmunoTech On Apr. 5 Approved Proposal From Polysciences For Manufacture Of AIM's Poly I And Poly C12U polynucleotides; Seperately Entered MArerial Transfer And Research Agreement With University of Cagliari Dipartimento di Scienze della Vita e dell'A   Benzinga
Mar 31, 2021
09:27AM EDT  AIM ImmunoTech Q4 EPS $(0.09) Up From $(0.33) YoY, Sales $42.00K Down From $50.00K YoY   Benzinga
09:15AM EDT  AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the fiscal year ended December 31, 2020 and provides a business update.   GlobeNewswire Inc
Mar 22, 2021
08:45AM EDT  AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to   GlobeNewswire Inc
Mar 11, 2021
07:00AM EST  via InvestorWire AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the Q1 Virtual Investor Summit.   GlobeNewswire Inc
Mar 10, 2021
06:55AM EST  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, AIMs Chief Executive Officer, has been invited to present at the Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC.   GlobeNewswire Inc
Mar 8, 2021
09:15AM EST  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has dosed the first healthy subjects in its Phase 1 clinical study on the safety of AIMs drug Ampligen as a potential intranasal therapy. AIMs s goal is to develop Ampligen as a potential intranasal prophylaxis or early-stage treatment for COVID-19 and other respiratory viral diseases.   GlobeNewswire Inc
Mar 4, 2021
06:50AM EST  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, will be presenting at the H.C. Wainwright Life Sciences Conference to be held virtually between March 9-10, 2021.   GlobeNewswire Inc
Feb 25, 2021
08:01AM EST  Aimia to Report 2020 Fourth Quarter Results   PR Newswire
Feb 24, 2021
01:57PM EST  AIM ImmunoTech Gets Orphan Drug Tag For Ampligen In Pancreatic Cancer   Benzinga
09:15AM EST  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its subsidiary, NV Hemispherx Biopharma Europe, has received formal notification from the European Commission (EC) approving the companys Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer.   GlobeNewswire Inc
Feb 16, 2021
09:36AM EST  AIM ImmunoTech Reports Its Ethics Committee Has Approved Commencement Of Phase 1 Study Of Ampligen As An Intranasal Therapy   Benzinga
09:15AM EST  AIM ImmunoTech Announces Ethics Committee Approval to Commence   GlobeNewswire Inc
Feb 10, 2021
11:17AM EST  AIM ImmunoTech To Include New Patients In Netherlands Pancreatic Cancer Program   Benzinga
09:59AM EST  AIM ImmunoTech Tweets Highlighting Earlier News '$AIM announced Dutch Health and Youth Care Inspectorate has approved #rintatolimod #Ampligen as a treatment for more #pancreaticcancer patients as part of a new Early Access Program'   Benzinga
09:17AM EST  AIM ImmunoTech Announces Dutch Health And Youth Care Inspectorate Has Approved Treatment For Six Pancreatic Cancer Patients As Part Of Early Access Program   Benzinga
09:15AM EST  AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer   GlobeNewswire Inc
Feb 5, 2021
06:50AM EST  AIM ImmunoTech Completes and Closes ATM Facility; Current Capital   GlobeNewswire Inc
Jan 29, 2021
07:45AM EST  The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO   Benzinga
06:55AM EST  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a sponsorship agreement with the Centre for Human Drug Research (CHDR) for the proposed AMP-COV-100 (CHDR2049) clinical study on the safety of AIMs drug Ampligen as an intranasal therapy, a critical step in the companys ongoing efforts to develop Ampligen as a COVID-19 treatment.   GlobeNewswire Inc
Jan 15, 2021
06:46AM EST  AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11:00 a.m. ET   Benzinga
06:45AM EST  AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has rescheduled its investor conference call for 11:00 a.m. Eastern Time on Thursday, January 21, 2021 to discuss the recently announced commencement of the treatment of subjects with COVID-19-induced chronic fatigue-like symptoms in the amended AMP-511 trial, recent accomplishments and upcoming milestones.   GlobeNewswire Inc
Jan 11, 2021
06:46AM EST  AIM ImmunoTech Postpones Investor Conference Call Due to Family Emergency   Benzinga
06:45AM EST  AIM ImmunoTech Inc. (NYSE American: AIM) and its CEO Thomas K. Equels today announced that this weeks planned investor conference call will be postponed and rescheduled for a later date following the death of Mr. Equels mother over this past weekend.   GlobeNewswire Inc
Jan 6, 2021
07:31AM EST  The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping   Benzinga
06:48AM EST  AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue 'Long Hauler' Patient Dosed with Ampligen   Benzinga
06:45AM EST  AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue   GlobeNewswire Inc
Dec 24, 2020
10:12AM EST  AIM ImmunoTech Announces Availability Of ME/CFS Trial Of Its Drug Ampligen For Enrollment To COVID-19 'Long Haulers'   RTTNews
09:10AM EST  AIM ImmunoTech Announces Availability Of ME/CFS Clinical Trial Of Co's Drug Ampligen For Enrollment To COVID-19 'Long Haulers'   Benzinga
09:05AM EST  AIM ImmunoTech Inc. (NYSE American: AIM) announced today that the post-COVID-19 Long Hauler portion of the active AMP-511 Expanded Access Program (EAP) protocol received approval from the Institutional Review Board (IRB) for a public notification of potential patient enrollment. Eligible patients enrolled in the trial receive treatment with AIMs flagship pipeline drug Ampligen.   GlobeNewswire Inc
07:53AM EST  AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers   Benzinga
Dec 23, 2020
05:36PM EST  AIM ImmunoTech Filing Shows Co. Added Pharmaceutics Int'l. As Fill & Finish Provider To Enhance Co. Capacity To Produce Ampligen   Benzinga
Dec 21, 2020
08:13AM EST  Benzinga Pro's Top 5 Stocks To Watch For Monday, Dec. 21, 2020: EYEG, NKE, ZM, WMT, AIM   Benzinga
06:48AM EST  AIM ImmunoTech Says FDA Grants Orphan Drug Designation Status To Ampligen For Pancreatic Cancer   RTTNews
06:46AM EST  AIM ImmunoTech Inc.'s Drug Ampligen Awarded FDA's Orphan Drug Designation Status for the Treatment of Pancreatic Cancer   Benzinga
06:45AM EST  AIM ImmunoTech Inc.s Drug Ampligen Awarded   GlobeNewswire Inc
Dec 15, 2020
06:31AM EST  Aimco Completes Separation Of Apartment Income REIT Corp.   Benzinga
Nov 25, 2020
11:01AM EST  Why These 3 Health Care Stocks Are Trading Higher Today   Benzinga
06:52AM EST  AIM ImmunoTech Announces Developments In Work To Develop New Treatments Or Preventive Strategies For COVID-19   RTTNews
06:47AM EST  AIM Says Is Also Working On Therapy For COVID-19 Long Haulers And An Intranasal Prophylaxis Strategy For Frontline Workers   Benzinga
06:46AM EST  AIM Announces First Patient Dosed In Study Evaluating Ampligen As Part Of Combination Treatment For Patients With Cancer And COVID-19   Benzinga
06:45AM EST  AIM ImmunoTech Inc. (NYSE American: AIM) today announced developments in its work to develop new treatments or preventive strategies for COVID-19, the disease caused by SARS-CoV-2.   GlobeNewswire Inc
Nov 23, 2020
09:12AM EST  AIM ImmunoTech Says Was Informed That First Patient Has Been Enrolled And Commenced Treatment In Phase 1/2a Study At Roswell Park Comprehensive Cancer Center Evaluating Ampligen With alpha-2b For Cancer And Mild-To-Moderate COVID-19   Benzinga
Nov 13, 2020
07:34AM EST  AIM ImmunoTech Late Thursday Reported Q3 EPS $(0.08) Up From $(1.13) YoY, Sales $36.00K Down From $61.00K YoY   Benzinga
07:30AM EST  AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today provided a business update for the third quarter ended September 30, 2020.   GlobeNewswire Inc
Nov 2, 2020
09:02AM EST  AIM ImmunoTech Highlights PLOS ONE's Publication of New Data Analyses Showing 'Importance of Disease Duration on Ampligen's Positive Role in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome'   Benzinga
09:00AM EST  AIM ImmunoTech Announces PLOS ONEs Publication   GlobeNewswire Inc
Oct 30, 2020
10:00AM EDT  BioFlorida Names AIM ImmunoTech CEO Thomas K. Equels as   GlobeNewswire Inc
Oct 22, 2020
07:30AM EDT  AIM ImmunoTech CEO to Participate in Virtual Panel Presentation at   GlobeNewswire Inc
Oct 6, 2020
09:06AM EDT  AIM ImmunoTech Announces IRB Approval To Enroll COVID-19 'Long Haulers' In AMP-511 ME/CFS Clinical Trial Of Ampligen   RTTNews
09:01AM EDT  AIM ImmunoTech Reports Institutional Review Board Approval For Expansion Of AMP-511 Expanded Access Program Trial For Myalgic Encephalomyelitis/Chronic Fatigue Syndrome To Include Patients Previously Diagnosed With SARS-CoV-2   Benzinga
09:01AM EDT  AIM ImmunoTech Announces IRB Approval to Enroll COVID-19   GlobeNewswire Inc
Sep 22, 2020
03:08PM EDT  Why AIM ImmunoTech's Stock Is Trading Higher Today   Benzinga
02:31PM EDT  Mid-Afternoon Market Update: Dow Rises 100 Points; AIM ImmunoTech Shares Climb   Benzinga
12:11PM EDT  Mid-Day Market Update: Nasdaq Gains 60 Points; Vaccinex Shares Slide   Benzinga
10:11AM EDT  Mid-Morning Market Update: Markets Mostly Higher; AutoZone Beats Q4 Estimates   Benzinga
06:52AM EDT  AIM ImmunoTech Announces Receipt Of 'Statistically Significant Positive Survival Results' In Pancreatic Cancer From A Early Access Program   Benzinga
Aug 27, 2020
09:18AM EDT  AIM ImmunoTech Says Decreases SARS-CoV-2 Infectious Viral Yields By 90% Using New In Vitro Model; Says Supports Further Testing of Ampligen as an Intranasal Prophylactic to Prevent COVID-19   Benzinga
Aug 21, 2020
11:18AM EDT  Insider Buys AIM ImmunoTech's Shares   Benzinga
Aug 17, 2020
07:00AM EDT  AIM ImmunoTech Provides Second Quarter 2020 Business Update   Benzinga
Jul 27, 2020
06:58AM EDT  AIM ImmunoTech Shares Move Higher; Co. Announces To Present At SNN Network Virtual Investor Conference On August 3   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC